



SEQUENCE LISTING

<110> DAWSON, GLYN
SEUNGUEN, JULIA CHO

<120> COMPOUNDS THAT ENHANCE TUMOR DEATH

<130> ARCD:351US

<140> 09/930,559

<141> 2001-08-15

<150> 60/225,526

<151> 2000-08-15

<160> 20

<170> PatentIn Ver. 2.1

<210> 1

<211> 2279

<212> DNA

<213> Human

<400> 1

```
ggcaccgagcg aagatggcgt cgcccggctg cctgtggctc ttggctgtgg ctctcctgcc 60
atggacctgc gcttctcggg cgctgcagca tctggaccgc ccggcgccgc tgcggttgg 120
gatctggcat gggatgggag acagctgttg caatccctta agcatgggtg ctattaaaaa 180
aatggtggag aagaaaatac ctggaattta cgtcttatct ttagagattg ggaagacct 240
gatggaggac gtggagaaca gcttcttctt gaatgtcaat tcccaagtaa caacagtgtg 300
tcaggcactt gctaaggatc cttaaattgca gcaaggctac aatgctatgg gattctccca 360
gggaggccaa tttctgaggg cagtggctca gagatgccct tcacctccca tgatcaatct 420
gatctcgggt gggggacaac atcaagggtg ttttggactc cctcgatgcc caggagagag 480
ctctcacatc tgtgacttca tccgaaaaac actgaatgct ggggcgtact ccaaagttgt 540
tcaggaaacg ctctgtcaag ccgaatactg gcatgacccc ataaaggagg atgtgtatcg 600
caaccacagc atcttcttgg cagatataaa tcaggagcgg ggtatcaatg agtcctacaa 660
gaaaaacctg atggccctga agaagtttgt gatggtgaaa ttcttcaatg attccattgt 720
ggaccctgta gattcggagt ggtttggatt ttacagaagt ggccaagcca aggaaacct 780
tcccttacag gagacctccc tgtacacaca ggaccgcctg gggctaaagg aaatggacaa 840
tgcaggacag ctagtgtttc tggctacaga aggggacct cttcagttgt ctgaagaatg 900
gttttatgcc cacatcatac cattccttgg atgaaacctg tatagttcac aatagagctc 960
agggagcccc taactcttcc aaaccacatg ggagacagtt tccttcatgc ccaagcctga 1020
gctcagatcc agcttgcaac taatccttct atcatctaac atgcactact tggaaagatc 1080
taagatctga atcttctctt ttgccatctt ctgttaccat atggtgttga atgcaagttt 1140
aattaccatg gagattgttt tacaaacttt tgatgtggtc aagttcagtt ttagaaaagg 1200
gagtcgtgtc cagatcaggg ccagaactgt gccaggccc aaaggagaca actaactaaa 1260
gtagtgagat agattctaag ggcaaacatt ttcccaagtc ttgccatatt tcaagcaaag 1320
aggtgcccag gcctgaggta ctcacataaa tgctttgttt tgctgggtgat ttaaccagt 1380
cttggaaaaa tcttgcttgg ctatttctgc atcatttctt aaggctgctt tcctctctga 1440
gtacgttgcc ctctgtgcta tcaatcatct tatcatcaat tattagacaa atcccactgg 1500
cctacagtct tgcttctgca gcacctact tgtctctca ggtagtgtg aattagttgc 1560
tgtcacaaaa ggagggaagt agcaccctaa ttaattgtct taagagagga aatgtacatc 1620
ttgtataact tagggagcga agaaaatgta ggcgcgaaag tgaaaagtga ggcagctagt 1680
tcttcttatt ccattctcga ccaacctgcc ctttcttaat atgactagtg gtcttgatgc 1740
tagagtcaac ttactctgtt gctggcttta gcagagaata ggaggaacca tatgaaaaag 1800
atcaggcttt ctgacttcca tccccaaaac acatttacca gcatactcca aactgtttct 1860
gatgtgttcc atgagaaaag gattgtttgc tcaaaaagct tggaaaatac tacacactcc 1920
```

ctttctcctt ctggagatca acccacatta gagtgtctaa ggactcctga gaattcctgt 1980
 tacagtaaac aaaactaacg taatctacca tttcctacac tatttgagca tggaaatcat 2040
 agtccccact ctatgaaaac ttaacgcttt ttggaagaca tttctgtagc atgtcagttt 2100
 ggagaaatga tgagctacgc cttgatgaaa gaaccgtggt ggtgctgcta agtttagcca 2160
 ttatgggtttt tcctttctct ctcttaagcc ttattcttca actaaaagat gaggattaag 2220
 agcaagaagt tgggggggat gtgaaaataa ttttatgagg ttgtctaaaa tctcgtgcc 2279

<210> 2

<211> 306

<212> PRT

<213> Human

<400> 2

Met	Ala	Ser	Pro	Gly	Cys	Leu	Trp	Leu	Leu	Ala	Val	Ala	Leu	Leu	Pro
1				5				10						15	
Trp	Thr	Cys	Ala	Ser	Arg	Ala	Leu	Gln	His	Leu	Asp	Pro	Pro	Ala	Pro
			20					25					30		
Leu	Pro	Leu	Val	Ile	Trp	His	Gly	Met	Gly	Asp	Ser	Cys	Cys	Asn	Pro
		35					40					45			
Leu	Ser	Met	Gly	Ala	Ile	Lys	Lys	Met	Val	Glu	Lys	Lys	Ile	Pro	Gly
	50					55					60				
Ile	Tyr	Val	Leu	Ser	Leu	Glu	Ile	Gly	Lys	Thr	Leu	Met	Glu	Asp	Val
65					70					75					80
Glu	Asn	Ser	Phe	Phe	Leu	Asn	Val	Asn	Ser	Gln	Val	Thr	Thr	Val	Cys
			85					90						95	
Gln	Ala	Leu	Ala	Lys	Asp	Pro	Lys	Leu	Gln	Gln	Gly	Tyr	Asn	Ala	Met
		100						105					110		
Gly	Phe	Ser	Gln	Gly	Gly	Gln	Phe	Leu	Arg	Ala	Val	Ala	Gln	Arg	Cys
	115						120					125			
Pro	Ser	Pro	Pro	Met	Ile	Asn	Leu	Ile	Ser	Val	Gly	Gly	Gln	His	Gln
	130					135					140				
Gly	Val	Phe	Gly	Leu	Pro	Arg	Cys	Pro	Gly	Glu	Ser	Ser	His	Ile	Cys
145				150						155					160
Asp	Phe	Ile	Arg	Lys	Thr	Leu	Asn	Ala	Gly	Ala	Tyr	Ser	Lys	Val	Val
			165						170					175	
Gln	Glu	Arg	Leu	Val	Gln	Ala	Glu	Tyr	Trp	His	Asp	Pro	Ile	Lys	Glu
		180						185					190		
Asp	Val	Tyr	Arg	Asn	His	Ser	Ile	Phe	Leu	Ala	Asp	Ile	Asn	Gln	Glu
	195					200						205			
Arg	Gly	Ile	Asn	Glu	Ser	Tyr	Lys	Lys	Asn	Leu	Met	Ala	Leu	Lys	Lys
	210					215					220				
Phe	Val	Met	Val	Lys	Phe	Leu	Asn	Asp	Ser	Ile	Val	Asp	Pro	Val	Asp

225 230 235 240
 Ser Glu Trp Phe Gly Phe Tyr Arg Ser Gly Gln Ala Lys Glu Thr Ile
 245 250 255
 Pro Leu Gln Glu Thr Ser Leu Tyr Thr Gln Asp Arg Leu Gly Leu Lys
 260 265 270
 Glu Met Asp Asn Ala Gly Gln Leu Val Phe Leu Ala Thr Glu Gly Asp
 275 280 285
 His Leu Gln Leu Ser Glu Glu Trp Phe Tyr Ala His Ile Ile Pro Phe
 290 295 300
 Leu Gly
 305

<210> 3
 <211> 7
 <212> PRT
 <213> Human

<400> 3
 Gly Cys Val Lys Ile Lys Lys
 1 5

<210> 4
 <211> 8
 <212> PRT
 <213> Human

<400> 4
 Ile Arg Tyr Cys Trp Leu Arg Arg
 1 5

<210> 5
 <211> 9
 <212> PRT
 <213> Human

<400> 5
 Val Thr Thr Leu Cys Cys Gly Lys Asn
 1 5

<210> 6
 <211> 7
 <212> PRT
 <213> Human

<400> 6
 Met Leu Cys Cys Met Arg Arg
 1 5

<210> 7
<211> 8
<212> PRT
<213> Human

<400> 7
Met Gly Cys Leu Gly Asn Ser Lys
1 5

<210> 8
<211> 10
<212> PRT
<213> Human

<400> 8
Gly Cys Met Ser Cys Lys Cys Val Leu Ser
1 5 10

<210> 9
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Primer

<400> 9
tctaggtacc aagatggcgt cgcccggtg cctgt 35

<210> 10
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Primer

<400> 10
acggtctaga tcatccaagg aatggtatga tgtgggca 38

<210> 11
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 11

Val Lys Ile Lys Lys
1 5

<210> 12
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 12
Tyr Cys Trp Leu Arg
1 5

<210> 13
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 13
Met Gly Cys Val Gln Cys Lys
1 5

<210> 14
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 14
Met Gly Cys Val Cys Ser Ser
1 5

<210> 15
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 15
Met Gly Cys Ile Lys Ser

1

5

<210> 16
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 16
Met Gly Ser Ser Lys Ser
1 5

<210> 17
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 17
Lys Leu Ala Lys Leu Ala Lys Lys Leu Ala Lys Leu Ala Lys
1 5 10

<210> 18
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 18
Leu Ala Leu Ala
1

<210> 19
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 19
Arg Tyr Cys Trp
1

<210> 20

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 20

Ala Cys Gly Cys Val Lys Ile Lys Lys

1

5